These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 18487578)

  • 1. Hormone receptor, grade, human epidermal growth factor receptor 2, and topoisomerase II as predictors of response to chemotherapy.
    Mehta RS
    J Clin Oncol; 2008 May; 26(15):2596; author reply 2596-7. PubMed ID: 18487578
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic strategies for triple-negative breast cancer.
    Tan AR; Swain SM
    Cancer J; 2008; 14(6):343-51. PubMed ID: 19060597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prognostic and predictive factors for endocrine treatment in breast carcinoma].
    Knoop AS; Rasmussen BB
    Ugeskr Laeger; 2007 Sep; 169(36):2997-9. PubMed ID: 17953880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tailored targeted therapy for all: a realistic and worthwhile objective against.
    Pritchard KI
    Breast Cancer Res; 2009; 11 Suppl 3(Suppl 3):S8. PubMed ID: 20030883
    [No Abstract]   [Full Text] [Related]  

  • 5. Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox.
    Mehta RS
    J Clin Oncol; 2008 Jul; 26(19):3286-8; author reply 3288. PubMed ID: 18591566
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical and pathological response to primary chemotherapy in patients with locally advanced breast cancer grouped according to hormonal receptors, Her2 status, grading and Ki-67 proliferation index.
    Miglietta L; Vanella P; Canobbio L; Parodi MA; Guglielmini P; Boccardo F
    Anticancer Res; 2009 May; 29(5):1621-5. PubMed ID: 19443376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptor status and ethnicity of indigent patients with breast cancer in New York City.
    Marti JL; Guth A; Naik A; Hiotis KL
    Arch Surg; 2008 Dec; 143(12):1227-30. PubMed ID: 19075177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.
    Millar EK; Graham PH; O'Toole SA; McNeil CM; Browne L; Morey AL; Eggleton S; Beretov J; Theocharous C; Capp A; Nasser E; Kearsley JH; Delaney G; Papadatos G; Fox C; Sutherland RL
    J Clin Oncol; 2009 Oct; 27(28):4701-8. PubMed ID: 19720911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of pathologic complete response in women treated with preoperative chemotherapy for locally advanced breast cancer: correlation of histology, hormone receptor status, Her2/Neu, and gross pathologic findings.
    Alvarado-Cabrero I; Alderete-Vázquez G; Quintal-Ramírez M; Patiño M; Ruíz E
    Ann Diagn Pathol; 2009 Jun; 13(3):151-7. PubMed ID: 19433292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basal and triple-negative breast cancers: impact on clinical decision-making and novel therapeutic options.
    Voduc D; Nielsen TO
    Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S171-8. PubMed ID: 19158038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human epidermal growth factor receptor-2 and topoisomerase II alpha expressions in rectal cancer.
    Liming S; Yuan Z; Qinghua D; Lei W; Qifeng J; Haojie L
    Hepatogastroenterology; 2011; 58(106):359-63. PubMed ID: 21661396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer.
    Broom RJ; Tang PA; Simmons C; Bordeleau L; Mulligan AM; O'Malley FP; Miller N; Andrulis IL; Brenner DM; Clemons MJ
    Anticancer Res; 2009 May; 29(5):1557-62. PubMed ID: 19443366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.
    Wei B; Wang J; Bourne P; Yang Q; Hicks D; Bu H; Tang P
    Hum Pathol; 2008 Dec; 39(12):1809-15. PubMed ID: 18715613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics.
    Kurebayashi J
    Breast Cancer; 2009; 16(4):275-80. PubMed ID: 19408071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapy.
    Kasami M; Uematsu T; Honda M; Yabuzaki T; Sanuki J; Uchida Y; Sugimura H
    Breast; 2008 Oct; 17(5):523-7. PubMed ID: 18534850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic and predictive factors in epithelial ovarian cancer].
    Boudou-Rouquette P; Pautier P; Morice P; Lhommé C
    Bull Cancer; 2009 Apr; 96(4):425-37. PubMed ID: 19357017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Topoisomerase II as a cellular receptor of various antineoplastic drugs].
    Szmigiero L
    Postepy Biochem; 1988; 34(3):147-52. PubMed ID: 2855749
    [No Abstract]   [Full Text] [Related]  

  • 18. The accuracy of preoperative core biopsy in determining histologic grade, hormone receptors, and human epidermal growth factor receptor 2 status in invasive breast cancer.
    Park SY; Kim KS; Lee TG; Park SS; Kim SM; Han W; Noh DY; Kim SW
    Am J Surg; 2009 Feb; 197(2):266-9. PubMed ID: 18614146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Use of molecular genetic analysis in selecting antitumor therapy].
    Imianitov EN; Moiseenko VM
    Vopr Onkol; 2008; 54(2):121-32. PubMed ID: 18522159
    [No Abstract]   [Full Text] [Related]  

  • 20. Molecular imaging as a tool for personalized and targeted anticancer therapy.
    McLarty K; Reilly RM
    Clin Pharmacol Ther; 2007 Mar; 81(3):420-4. PubMed ID: 17339871
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.